Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NKGen Biotech ( (NKGN) ) has provided an update.
NKGen Biotech has been chosen as the stalking horse bidder for NKMax in a court-managed rehabilitation process in South Korea, promising significant developments in NK cell therapies. This acquisition could secure global intellectual property rights for NKGen and facilitate the commercialization of troculeucel in markets where NK cell therapy is legal, such as Japan and South Korea. With up to $18 million in committed funding, the deal is anticipated to close in Q1 2025, potentially bolstering NKGen’s position in global cell therapy markets.
See more insights into NKGN stock on TipRanks’ Stock Analysis page.